

# Elena Castro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4163312/publications.pdf>

Version: 2024-02-01

65  
papers

4,620  
citations

172457

29  
h-index

114465

63  
g-index

66  
all docs

66  
docs citations

66  
times ranked

6308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2022, 23, 362-373.	10.7	97
2	Implications of DNA damage repair alterations for the management of prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 302-310.	1.8	1
3	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	3.7	15
4	TP53: Another Piece of the Prostate Cancer Genetics Puzzle. <i>European Urology</i> , 2022, 81, 251-252.	1.9	1
5	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	3.7	9
6	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	6.4	63
7	Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 315-318.	5.4	6
8	DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review. <i>Future Oncology</i> , 2021, 17, 853-864.	2.4	3
9	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021, 79, 519-529.	1.9	30
10	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	2.8	42
11	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , 2021, 13, 2334.	3.7	9
12	B2B: Prostate Cancer. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, S30-S50.	0.4	0
13	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4
14	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2021, 22, 1250-1264.	10.7	159
15	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	3.7	22
16	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
17	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology, The</i> , 2021, 22, 1618-1631.	10.7	48
18	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 2855.	3.7	16
20	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	1.3	58
21	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
22	Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 763-766.	1.9	9
23	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
24	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	3.7	54
25	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
26	BRCA2 and Other DDR Genes in Prostate Cancer. <i>Cancers</i> , 2019, 11, 352.	3.7	72
27	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 490-503.	1.6	255
28	Importancia del radio-223 en la práctica hospitalaria. Visión del oncólogo médico. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2019, 38, 106-111.	0.0	0
29	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
30	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
31	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	1.9	80
32	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq0 0 OqBT /Overlock 10 Tf		
33	Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 164-164.	1.6	2
34	Inherited mutations in DNA repair genes and cancer risk. <i>Current Problems in Cancer</i> , 2017, 41, 251-264.	2.0	28
35	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. <i>Psycho-Oncology</i> , 2017, 26, 1987-1993.	2.3	12
36	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142

#	ARTICLE	IF	CITATIONS
37	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , 2017, 71, 417-425.	1.9	169
38	Targeting DNA Repair. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 353-356.	2.0	27
39	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016, 21, 716-722.	3.7	27
40	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. <i>Psycho-Oncology</i> , 2015, 24, 1492-1499.	2.3	23
41	Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomarkers?. <i>Annals of Oncology</i> , 2015, 26, 622-623.	1.2	3
42	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e19-202.e28.	1.6	8
43	High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. <i>Annals of Oncology</i> , 2015, 26, 2293-2300.	1.2	36
44	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. <i>European Urology</i> , 2015, 68, 186-193.	1.9	279
45	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. <i>European Journal of Radiology Open</i> , 2014, 1, 22-27.	1.6	6
46	Men are all very well reading the letters in the genome, but it's a long way to being able to write interpretations of undergoing genetic profiling to determine future risk of prostate cancer. <i>Familial Cancer</i> , 2014, 13, 625-635.	1.9	15
47	Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 158-165.	2.4	6
48	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
49	The genetic epidemiology of prostate cancer and its clinical implications. <i>Nature Reviews Urology</i> , 2014, 11, 18-31.	3.8	207
50	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1748-1757.	1.6	641
51	Re: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 2093-2094.	0.4	3
52	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.5	105
53	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
54	Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. <i>BJU International</i> , 2013, 112, 666-673.	2.5	34

#	ARTICLE	IF	CITATIONS
55	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Scientific Reports, 2013, 3, 2059.	3.3	26
56	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e50-e55.	3.8	12
57	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e50-e55.	3.8	7
58	Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 2012, 106, 1697-1701.	6.4	251
59	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, The, 2012, 13, 1114-1124.	10.7	125
60	The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 2012, 14, 409-414.	1.6	124
61	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Human Genetics, 2011, 129, 687-694.	3.8	83
62	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
63	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 2011, 105, 1230-1234.	6.4	320
64	The risk of taking the part by the whole. Annals of Oncology, 2008, 19, 1975-1976.	1.2	0
65	Third Nerve Palsy as the Initial Presenting Sign of Metastatic Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 407-408.	1.3	3